Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Fosaprepitant

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: Fosaprepitant. Displaying page 1 of 1.
    EudraCT Number: 2012-002340-24 Sponsor Protocol Number: 0517-029 Start Date*: 2012-10-26
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase IIb, Partially-Blinded, Randomized, Active Comparator-Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Fosaprepitant in Pediatric Patients for...
    Medical condition: Chemotherapy-induced nausea and vomiting (CINV) associated with emetogenic chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    15.0 10042613 - Surgical and medical procedures 10036899 Prophylaxis against chemotherapy induced vomiting LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) PT (Completed) DE (Completed) AT (Completed) HU (Completed) EE (Completed) GB (Completed) LT (Completed) GR (Completed) IT (Completed) RO (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-004043-30 Sponsor Protocol Number: 0517-017 Start Date*: 2008-01-08
    Sponsor Name:Merck Sharp & Dohme (Sweden) AB
    Full Title: A Phase III, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of a Single Dose of I...
    Medical condition: Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated with Cisplatin Chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054133 Prophylaxis of nausea and vomiting LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) IT (Completed) HU (Completed) PT (Completed) PL (Completed) NL (Completed) LT (Completed) DK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001783-34 Sponsor Protocol Number: MK-0517-044 Start Date*: 2015-08-05
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A phase III, randomized, placebo-controlled clinical trial to study the efficacy and safety of MK-0517/fosaprepitant and ondansetron versus ondansetron for the prevention of chemotherapy-induced na...
    Medical condition: Chemotherapy-induced nausea and vomiting (CINV) associated with emetogenic chemotherapy
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) NO (Completed) ES (Completed) LT (Completed) FI (Completed) PT (Completed) EE (Completed) HU (Completed) GB (Completed) NL (Completed) GR (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-001718-41 Sponsor Protocol Number: 0517-31 Start Date*: 2012-09-04
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of...
    Medical condition: chemotherapy induced nausea and vomiting
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) NL (Completed) ES (Completed) CZ (Completed) SE (Completed) HU (Completed) IT (Completed) PT (Completed) LV (Completed) PL (Completed) BG (Completed) GR (Completed) NO (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2006-005515-10 Sponsor Protocol Number: 0869-134 Start Date*: 2009-01-22
    Sponsor Name:Merck & Co., Inc
    Full Title: "Estudio multicéntrico, abierto, de 5 partes para evaluar la farmacocinética, seguridad y tolerabilidad del aprepitant y de la dimeglumina de fosaprepitant en pacientes pediátricos que reciben quim...
    Medical condition: Nauseas y vómitos inducidos por quimioterapia Chemotherapy induced nausea and vomiting (CINV)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056989 Nausea post chemotherapy LLT
    9.1 10036899 Prophylaxis against chemotherapy induced vomiting LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) SE (Completed) DE (Prematurely Ended) FR (Completed) Outside EU/EEA HU (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004844-43 Sponsor Protocol Number: MK-0517-045 Start Date*: 2019-10-07
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 4, Open-label, Single Arm Study to Evaluate the Safety and Tolerability of a Three-day Fosaprepitant Regimen Administered for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CIN...
    Medical condition: Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10054133 Prophylaxis of nausea and vomiting PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) LT (Completed) PL (Completed) HU (Completed) NL (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2015-003070-33 Sponsor Protocol Number: DANSAC-RCT Start Date*: 2015-11-30
    Sponsor Name:Odense University Hospital
    Full Title: DANSAC-RCT: Fosaprepitant in patients with advanced cancer not receiving chemotherapy or irradiation; A multicenter, randomized, double-blind, placebo-controlled study.
    Medical condition: Emesis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10017947 - Gastrointestinal disorders 10028817 Nausea and vomiting symptoms HLT
    18.1 10017947 - Gastrointestinal disorders 10014542 Emesis LLT
    18.1 10017947 - Gastrointestinal disorders 10028813 Nausea PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-014691-21 Sponsor Protocol Number: GAND-emesis Start Date*: 2010-01-27
    Sponsor Name:Odense University Hospital
    Full Title: GAND-emesis: A multinational, randomized, double-blind, placebo-controlled, parallel-group study to investigate the efficacy and tolerability of palonosetron and dexamethasone plus the neurokinin1...
    Medical condition: The study aims at investigating if a three-drug antiemetic regimen is superior in preventing nausea and vomiting in patients receiving radiotherapy and weekly chemotherapy than a two-drug regimen (...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10036902 Prophylaxis against radiation induced nausea and vomiting LLT
    14.1 10042613 - Surgical and medical procedures 10008449 Chemotherapy inducted emesis prophylaxis LLT
    14.1 10042613 - Surgical and medical procedures 10054133 Prophylaxis of nausea and vomiting PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003512-22 Sponsor Protocol Number: 0869-130 Start Date*: 2006-11-23
    Sponsor Name:Laboratoires Merck Sharp & Dohme-Chibret
    Full Title: A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nau...
    Medical condition: Chemotherapy-induced Nausea and Vomitting
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000663-80 Sponsor Protocol Number: ONO-7847-03 Start Date*: 2018-02-16
    Sponsor Name:Ono Pharmaceutical Co., Ltd.
    Full Title: ONO-7847 Japanese Clinical Study in Pediatric Patients Multicenter, open-label, uncontrolled study for the prevention of CINV
    Medical condition: Chemotherapy-induced nausea and vomiting (CINV) associated with emetogenic chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10036899 Prophylaxis against chemotherapy induced vomiting LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-001635-51 Sponsor Protocol Number: DN10016 Start Date*: 2013-08-01
    Sponsor Name:Acacia Pharma Ltd
    Full Title: Randomised, double-blind, dose-finding Phase II study to assess the efficacy of APD403 in the prevention of nausea and vomiting caused by cisplatin- or anthracycline/ cyclophosphamide (AC)-based ch...
    Medical condition: Chemotherapy-induced nausea and vomiting
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004865 10049091 Chemotherapy antiemetic prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 28 22:05:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA